Challenges of the Immunotherapy: Perspectives and Limitations of the Immune Checkpoint Inhibitor Treatment

被引:65
作者
Dobosz, Paula [1 ]
Stepien, Maria [2 ,3 ]
Golke, Anna [4 ]
Dzieciatkowski, Tomasz [5 ]
机构
[1] Minist Interior Affairs & Adm Warsaw, Dept Genet & Genom, Cent Clin Hosp, PL-02507 Warsaw, Poland
[2] Med Univ Lublin, Dept Infect Dis, PL-20059 Lublin, Poland
[3] Med Univ Lublin, Dept Sports Med, PL-20059 Lublin, Poland
[4] Warsaw Univ Life Sci, Inst Vet Med, Dept Preclin Sci, PL-02776 Warsaw, Poland
[5] Med Univ Warsaw, Chair & Dept Med Microbiol, PL-02005 Warsaw, Poland
关键词
checkpoint inhibitors; immunotherapy; cancer; tumour microenvironment; immune system; LUNG-CANCER; T-CELLS; PD-1; BLOCKADE; ACQUIRED-RESISTANCE; ANTITUMOR IMMUNITY; CTLA-4; OPEN-LABEL; MECHANISMS; IPILIMUMAB; PATHWAYS;
D O I
10.3390/ijms23052847
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Immunotherapy is a quickly developing type of treatment and the future of therapy in oncology. This paper is a review of recent findings in the field of immunotherapy with an emphasis on immune checkpoint inhibitors. The challenges that immunotherapy might face in near future, such as primary and acquired resistance and the irAEs, are described in this article, as well as the perspectives such as identification of environmental modifiers of immunity and development of anti-cancer vaccines and combined therapies. There are multiple factors that may be responsible for immunoresistance, such as genomic factors, factors related to the immune system cells or to the cancer microenvironment, factors emerging from the host cells, as well as other factors such as advanced age, biological sex, diet, many hormones, existing comorbidities, and the gut microbiome.
引用
收藏
页数:17
相关论文
共 120 条
[1]   Anti-CD73 therapy impairs tumor angiogenesis [J].
Allard, Bertrand ;
Turcotte, Martin ;
Spring, Kathleen ;
Pommey, Sandra ;
Royal, Isabelle ;
Stagg, John .
INTERNATIONAL JOURNAL OF CANCER, 2014, 134 (06) :1466-1473
[2]   Incidence and risk of significantly raised blood pressure in cancer patients treated with bevacizumab: an updated meta-analysis [J].
An, Mao Mao ;
Zou, Zui ;
Shen, Hui ;
Liu, Ping ;
Chen, Meng Li ;
Cao, Yong Bing ;
Jiang, Yuan Ying .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 66 (08) :813-821
[3]   In vivo imaging reveals a tumor-associated macrophage-mediated resistance pathway in anti-PD-1 therapy [J].
Arlauckas, Sean P. ;
Garris, Christopher S. ;
Kohler, Rainer H. ;
Kitaoka, Maya ;
Cuccarese, Michael F. ;
Yang, Katherine S. ;
Miller, Miles A. ;
Carlson, Jonathan C. ;
Freeman, Gordon J. ;
Anthony, Robert M. ;
Weissleder, Ralph ;
Pittet, Mikael J. .
SCIENCE TRANSLATIONAL MEDICINE, 2017, 9 (389)
[4]   Conserved pan-cancer microenvironment subtypes predict response to immunotherapy [J].
Bagaev, Alexander ;
Kotlov, Nikita ;
Nomie, Krystle ;
Svekolkin, Viktor ;
Gafurov, Azamat ;
Isaeva, Olga ;
Osokin, Nikita ;
Kozlov, Ivan ;
Frenkel, Felix ;
Gancharova, Olga ;
Almog, Nava ;
Tsiper, Maria ;
Ataullakhanov, Ravshan ;
Fowler, Nathan .
CANCER CELL, 2021, 39 (06) :845-+
[5]   Mechanisms of Cancer Resistance to Immunotherapy [J].
Bai, Rilan ;
Chen, Naifei ;
Li, Lingyu ;
Du, Nawen ;
Bai, Ling ;
Lv, Zheng ;
Tian, Huimin ;
Cui, Jiuwei .
FRONTIERS IN ONCOLOGY, 2020, 10
[6]   Are anti-PD1 and anti-PD-L1 alike? The non-small-cell lung cancer paradigm [J].
Banna, Giuseppe Luigi ;
Cantale, Ornella ;
Bersanelli, Melissa ;
Del Re, Marzia ;
Friedlaender, Alex ;
Cortellini, Alessio ;
Addeo, Alfredo .
ONCOLOGY REVIEWS, 2020, 14 (02) :135-143
[7]   Non-small-cell lung cancer brain metastases and PD-(L)1 immune checkpoint inhibitors [J].
Barlesi, Fabrice ;
Tomasini, Pascale .
LANCET ONCOLOGY, 2020, 21 (05) :607-608
[8]  
Beavis PA, 2015, ONCOIMMUNOLOGY, V4
[9]   Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop [J].
Bedognetti, Davide ;
Ceccarelli, Michele ;
Galluzzi, Lorenzo ;
Lu, Rongze ;
Palucka, Karolina ;
Samayoa, Josue ;
Spranger, Stefani ;
Warren, Sarah ;
Wong, Kwok-Kin ;
Ziv, Elad ;
Chowell, Diego ;
Coussens, Lisa M. ;
De Carvalho, Daniel D. ;
DeNardo, David G. ;
Galon, Jerome ;
Kaufman, Howard L. ;
Kirchhoff, Tomas ;
Lotze, Michael T. ;
Luke, Jason J. ;
Minn, Andy J. ;
Politi, Katerina ;
Shultz, Leonard D. ;
Simon, Richard ;
Thorsson, Vesteinn ;
Weidhaas, Joanne B. ;
Ascierto, Maria Libera ;
Ascierto, Paolo Antonio ;
Barnes, James M. ;
Barsan, Valentin ;
Bommareddy, Praveen K. ;
Bot, Adrian ;
Church, Sarah E. ;
Ciliberto, Gennaro ;
De Maria, Andrea ;
Draganov, Dobrin ;
Ho, Winson S. ;
McGee, Heather M. ;
Monette, Anne ;
Murphy, Joseph F. ;
Nistico, Paola ;
Park, Wungki ;
Patel, Maulik ;
Quigley, Michael ;
Radvanyi, Laszlo ;
Raftopoulos, Harry ;
Rudqvist, Nils-Petter ;
Snyder, Alexandra ;
Sweis, Randy F. ;
Valpione, Sara ;
Butterfield, Lisa H. .
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
[10]   Cellular and molecular mechanisms in cancer immune escape: a comprehensive review [J].
Bhatia, Alka ;
Kumar, Yashwant .
EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2014, 10 (01) :41-62